Beneficial effects of metformin supplementation in hypothalamic paraventricular nucleus and arcuate nucleus of type 2 diabetic rats. 2022

Xiao-Jing Yu, and Yan-Mei Chen, and Xiao-Jing Liu, and Xiao-Jie Bai, and Kai-Li Liu, and Li-Yan Fu, and Hong-Li Gao, and Tian-Ze Sun, and Xiao-Lian Shi, and Jie Qi, and Ying Li, and Yu-Ming Kang
Department of Physiology and Pathophysiology, Xi'an Jiaotong University School of Basic Medical Sciences, Shaanxi Engineering and Research Center of Vaccine, Key Laboratory of Environment and Genes Related to Diseases of Education Ministry of China, Xi'an 710061, China.

Background Oxidative stress and inflammation play important roles in the development of diabetes. Metformin (MET) is considered as the first-line therapy for patients with type 2 diabetes (T2D). Hypothalamic paraventricular nucleus (PVN) and hypothalamic arcuate nucleus (ARC) are vital in obesity and diabetes. However, there have been few studies on the effects of MET on inflammatory reaction and oxidative stress in the PVN and ARC of T2D diabetic rats. Methods Male Sprague-Dawley (SD) rats were fed with high-fat diet (HFD), and intraperitoneally injected with low-dose streptozotocin (STZ, 30 mg/kg) at 6th week to induce T2D diabetes. After injection of STZ, they were fed with HFD continually. Starting from the 8th week of HFD feeding, T2D rats received intragastrical administration of MET (150 mg/kg/day) in addition to the HFD for another 8 weeks. At the end of the 15th week, the rats were anaesthetized to record the sympathetic nerve activity and collect blood and tissue samples. Results In comparison with control rats, T2D diabetic rats had higher levels of pro-inflammatory cytokines (PICs) and excessive oxidative stress in the PVN and ARC, accompanied with more activated astrocytes. The renal sympathetic nerve activity (RSNA) and the plasma norepinephrine (NE) increased in T2D diabetic rats. The expression of tyrosine hydroxylase (TH) increased and the expression of 67-kDa isoform of glutamate decarboxylase (GAD67) decreased in T2D diabetic rats. Supplementation of MET decreased blood glucose, suppressed RSNA, decreased PICs (TNF-α, IL-1β and IL-6) in PVN and ARC, attenuated oxidative stress and activation of astrocytes in ARC and PVN of T2D diabetic rats, as well as restored the balance of neurotransmitter synthetase. The number of Fra-LI (chronic neuronal excitation marker) positive neurons in the ARC and PVN of T2D diabetic rats increased. Chronic supplementation of MET also decreased the number of Fra-LI positive neurons in the ARC and PVN of T2D diabetic rats. Conclusion These findings suggest that the PVN and ARC participate in the beneficial effects of MET in T2D diabetic rats, which is possibly mediated via down-regulating of inflammatory molecules, attenuating oxidative stress and restoring the balance of neurotransmitter synthetase by MET in the PVN and ARC.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008297 Male Males
D008687 Metformin A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289) Dimethylguanylguanidine,Dimethylbiguanidine,Glucophage,Metformin HCl,Metformin Hydrochloride,HCl, Metformin,Hydrochloride, Metformin
D010286 Paraventricular Hypothalamic Nucleus Nucleus in the anterior part of the HYPOTHALAMUS. Hypothalamic Paraventricular Nucleus,Paraventricular Nucleus,Hypothalamic Nucleus, Paraventricular,Nucleus, Hypothalamic Paraventricular,Nucleus, Paraventricular,Nucleus, Paraventricular Hypothalamic,Paraventricular Nucleus, Hypothalamic
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005968 Glutamate Decarboxylase A pyridoxal-phosphate protein that catalyzes the alpha-decarboxylation of L-glutamic acid to form gamma-aminobutyric acid and carbon dioxide. The enzyme is found in bacteria and in invertebrate and vertebrate nervous systems. It is the rate-limiting enzyme in determining GAMMA-AMINOBUTYRIC ACID levels in normal nervous tissues. The brain enzyme also acts on L-cysteate, L-cysteine sulfinate, and L-aspartate. EC 4.1.1.15. Glutamate Carboxy-Lyase,Glutamic Acid Decarboxylase,Acid Decarboxylase, Glutamic,Carboxy-Lyase, Glutamate,Decarboxylase, Glutamate,Decarboxylase, Glutamic Acid,Glutamate Carboxy Lyase
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Xiao-Jing Yu, and Yan-Mei Chen, and Xiao-Jing Liu, and Xiao-Jie Bai, and Kai-Li Liu, and Li-Yan Fu, and Hong-Li Gao, and Tian-Ze Sun, and Xiao-Lian Shi, and Jie Qi, and Ying Li, and Yu-Ming Kang
August 1998, Neuroendocrinology,
Xiao-Jing Yu, and Yan-Mei Chen, and Xiao-Jing Liu, and Xiao-Jie Bai, and Kai-Li Liu, and Li-Yan Fu, and Hong-Li Gao, and Tian-Ze Sun, and Xiao-Lian Shi, and Jie Qi, and Ying Li, and Yu-Ming Kang
January 2012, PloS one,
Xiao-Jing Yu, and Yan-Mei Chen, and Xiao-Jing Liu, and Xiao-Jie Bai, and Kai-Li Liu, and Li-Yan Fu, and Hong-Li Gao, and Tian-Ze Sun, and Xiao-Lian Shi, and Jie Qi, and Ying Li, and Yu-Ming Kang
January 1997, Annals of the New York Academy of Sciences,
Xiao-Jing Yu, and Yan-Mei Chen, and Xiao-Jing Liu, and Xiao-Jie Bai, and Kai-Li Liu, and Li-Yan Fu, and Hong-Li Gao, and Tian-Ze Sun, and Xiao-Lian Shi, and Jie Qi, and Ying Li, and Yu-Ming Kang
January 1995, Neurobiology (Budapest, Hungary),
Xiao-Jing Yu, and Yan-Mei Chen, and Xiao-Jing Liu, and Xiao-Jie Bai, and Kai-Li Liu, and Li-Yan Fu, and Hong-Li Gao, and Tian-Ze Sun, and Xiao-Lian Shi, and Jie Qi, and Ying Li, and Yu-Ming Kang
January 1995, Acta anatomica,
Xiao-Jing Yu, and Yan-Mei Chen, and Xiao-Jing Liu, and Xiao-Jie Bai, and Kai-Li Liu, and Li-Yan Fu, and Hong-Li Gao, and Tian-Ze Sun, and Xiao-Lian Shi, and Jie Qi, and Ying Li, and Yu-Ming Kang
January 1999, Zhurnal evoliutsionnoi biokhimii i fiziologii,
Xiao-Jing Yu, and Yan-Mei Chen, and Xiao-Jing Liu, and Xiao-Jie Bai, and Kai-Li Liu, and Li-Yan Fu, and Hong-Li Gao, and Tian-Ze Sun, and Xiao-Lian Shi, and Jie Qi, and Ying Li, and Yu-Ming Kang
October 1998, World journal of gastroenterology,
Xiao-Jing Yu, and Yan-Mei Chen, and Xiao-Jing Liu, and Xiao-Jie Bai, and Kai-Li Liu, and Li-Yan Fu, and Hong-Li Gao, and Tian-Ze Sun, and Xiao-Lian Shi, and Jie Qi, and Ying Li, and Yu-Ming Kang
May 2008, Neurochemical research,
Xiao-Jing Yu, and Yan-Mei Chen, and Xiao-Jing Liu, and Xiao-Jie Bai, and Kai-Li Liu, and Li-Yan Fu, and Hong-Li Gao, and Tian-Ze Sun, and Xiao-Lian Shi, and Jie Qi, and Ying Li, and Yu-Ming Kang
August 2016, American journal of physiology. Heart and circulatory physiology,
Xiao-Jing Yu, and Yan-Mei Chen, and Xiao-Jing Liu, and Xiao-Jie Bai, and Kai-Li Liu, and Li-Yan Fu, and Hong-Li Gao, and Tian-Ze Sun, and Xiao-Lian Shi, and Jie Qi, and Ying Li, and Yu-Ming Kang
July 2006, Hypertension (Dallas, Tex. : 1979),
Copied contents to your clipboard!